What is PBYI's current stock price?

PBYI (Puma Biotechnology, Inc.) is currently trading at $7.08 with a market cap of $360.4M.

What sector is Puma Biotechnology, Inc. in?

Puma Biotechnology, Inc. (PBYI) operates in the Healthcare sector, specifically in the Biotechnology industry.

InvestLog

PBYI Puma Biotechnology, Inc.

Healthcare

$7.08+0.43%ClosedMarket Cap: $360.4M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

11.41

PEG

4.35

P/B

2.80

P/S

1.59

EV/EBITDA

7.77

DCF Value

$16.70

FCF Yield

14.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

74.5%

Operating Margin

13.0%

Net Margin

10.7%

ROE

20.4%

ROA

12.7%

ROIC

17.1%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$44.8M	$-3.8M	$—
Q4 null	$75.5M	$13.4M	$—
FY null	$228.4M	$31.1M	$—
Q3 null	$54.5M	$8.8M	$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

0 Strong Buy0 Buy1 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All

NOUGUES MAXIMO Fofficer: Chief Financial Officer

SellFri Feb 20

NOUGUES MAXIMO Fofficer: Chief Financial Officer

SellFri Feb 20

HUNT DOUGLAS Mofficer: See Remarks

SellFri Feb 20

HUNT DOUGLAS Mofficer: See Remarks

SellFri Feb 20

AUERBACH ALAN Hdirector, 10 percent owner, officer: President and CEO

SellFri Feb 20

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.23

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Peers